Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 4
2012 1
2013 1
2014 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
PGE2-induced colon cancer growth is mediated by mTORC1.
Dufour M, Faes S, Dormond-Meuwly A, Demartines N, Dormond O. Dufour M, et al. Among authors: dormond meuwly a. Biochem Biophys Res Commun. 2014 Sep 5;451(4):587-91. doi: 10.1016/j.bbrc.2014.08.032. Epub 2014 Aug 13. Biochem Biophys Res Commun. 2014. PMID: 25128827
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives.
Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Dufour M, et al. Among authors: dormond meuwly a. Cancers (Basel). 2011 May 24;3(2):2478-500. doi: 10.3390/cancers3022478. Cancers (Basel). 2011. PMID: 24212820 Free PMC article.
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells.
Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N, Dormond O. Blaser B, et al. Among authors: dormond meuwly a. BMC Cancer. 2012 Mar 8;12:86. doi: 10.1186/1471-2407-12-86. BMC Cancer. 2012. PMID: 22401294 Free PMC article.
Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells.
Benoit M, Dormond-Meuwly A, Demartines N, Dormond O. Benoit M, et al. Among authors: dormond meuwly a. J Surg Res. 2011 May 15;167(2):e193-8. doi: 10.1016/j.jss.2011.01.015. Epub 2011 Feb 5. J Surg Res. 2011. PMID: 21324487
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O. Roulin D, et al. Among authors: dormond meuwly a. Mol Cancer. 2011 Jul 26;10:90. doi: 10.1186/1476-4598-10-90. Mol Cancer. 2011. PMID: 21791089 Free PMC article.
Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of rapamycin.
Abdelnour-Berchtold E, Cerantola Y, Roulin D, Dormond-Meuwly A, Demartines N, Dormond O. Abdelnour-Berchtold E, et al. Among authors: dormond meuwly a. Anticancer Res. 2010 Mar;30(3):799-804. Anticancer Res. 2010. PMID: 20392999
The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Dormond-Meuwly A, Roulin D, Dufour M, Benoit M, Demartines N, Dormond O. Dormond-Meuwly A, et al. Biochem Biophys Res Commun. 2011 Apr 22;407(4):714-9. doi: 10.1016/j.bbrc.2011.03.086. Epub 2011 Mar 23. Biochem Biophys Res Commun. 2011. PMID: 21439267
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo.
Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Roulin D, et al. Among authors: dormond meuwly a. Mol Cancer. 2010 Mar 12;9:57. doi: 10.1186/1476-4598-9-57. Mol Cancer. 2010. PMID: 20226010 Free PMC article.
Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.
Dufour M, Dormond-Meuwly A, Pythoud C, Demartines N, Dormond O. Dufour M, et al. Among authors: dormond meuwly a. Biochem Biophys Res Commun. 2013 Aug 16;438(1):32-7. doi: 10.1016/j.bbrc.2013.07.014. Epub 2013 Jul 15. Biochem Biophys Res Commun. 2013. PMID: 23867821
Feedback